AC-93253 triggers the downregulation of melanoma progression markers and the inhibition of melanoma cell proliferation

Chemico-Biological Interactions

Volumn 236, Issue , 2015, Pages 9-18

  Karwaciak, Iwona ^a   Gorzkiewicz, Michal ^a   Ryba, Katarzyna ^a   Dastych, Jaroslaw ^a   Pulaski, Lukasz ^a   Ratajewski, Marcin ^a  

^a INSTITUTE OF MEDICAL BIOLOGY   (Poland)

Author keywords

ABC transporters; AC 93253; Melanoma; Resistance; SIRT

Indexed keywords

ABC TRANSPORTER; AC 93253; CYTOTOXIC AGENT; DOXORUBICIN; PROTEIN INHIBITOR; SIRTUIN 2; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZOTHIAZOLE DERIVATIVE; SIRT2 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE REGULATION; CELL PROLIFERATION; DOWN REGULATION; DRUG EFFICACY; DRUG STRUCTURE; GENE EXPRESSION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; ONCOGENE; STRUCTURE ANALYSIS; ANTAGONISTS AND INHIBITORS; CELL CYCLE G1 PHASE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MULTIGENE FAMILY; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; BENZOTHIAZOLES; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DOXORUBICIN; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MULTIGENE FAMILY; SIRTUIN 2; TUMOR MARKERS, BIOLOGICAL;

EID: 84929469705     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2015.04.016     Document Type: Article

References (64)

1. V.A. Nikolaou, A.J. Stratigos, K.T. Flaherty, and H. Tsao Melanoma: new insights and new therapies J. Invest. Dermatol. 132 2012 854 863
2. M. Chartrain, J. Riond, A. Stennevin, I. Vandenberghe, B. Gomes, L. Lamant, N. Meyer, J.E. Gairin, N. Guilbaud, and J.P. Annereau Melanoma chemotherapy leads to the selection of ABCB5-expressing cells PLoS One 7 2012 e36762
3. K.P. Hoeflich, D.C. Gray, M.T. Eby, J.Y. Tien, L. Wong, J. Bower, A. Gogineni, J. Zha, M.J. Cole, H.M. Stern, L.J. Murray, D.P. Davis, and S. Seshagiri Oncogenic BRAF is required for tumor growth and maintenance in melanoma models Cancer Res. 66 2006 999 1006
4. L.A. Garraway, H.R. Widlund, M.A. Rubin, G. Getz, A.J. Berger, S. Ramaswamy, R. Beroukhim, D.A. Milner, S.R. Granter, J. Du, C. Lee, S.N. Wagner, C. Li, T.R. Golub, D.L. Rimm, M.L. Meyerson, D.E. Fisher, and W.R. Sellers Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma Nature 436 2005 117 122
5. S. Mocellin, L. Bertazza, C. Benna, and P. Pilati Circumventing melanoma chemoresistance by targeting DNA repair Curr. Med. Chem. 19 2012 3893 3899
6. M. Tiago, E.M. de Oliveira, C.A. Brohem, P.C. Pennacchi, R.D. Paes, R.B. Haga, A. Campa, S.B. de Moraes Barros, K.S. Smalley, and S.S. Maria-Engler Fibroblasts protect melanoma cells from the cytotoxic effects of doxorubicin Tissue Eng. A 20 2014 2412 2421
7. L.B. Jilaveanu, S.A. Aziz, and H.M. Kluger Chemotherapy and biologic therapies for melanoma: do they work? Clin. Dermatol. 27 2009 614 625
8. J. Thumar, D. Shahbazian, S.A. Aziz, L.B. Jilaveanu, and H.M. Kluger MEK targeting in N-RAS mutated metastatic melanoma Mol. Cancer 13 2014 45
9. K. Azijli, E. Stelloo, G.J. Peters, and V.D.E. AJ New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies Anticancer Res. 34 2014 1493 1505
10. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H. Woffendin, M.J. Garnett, W. Bottomley, N. Davis, E. Dicks, R. Ewing, Y. Floyd, K. Gray, S. Hall, R. Hawes, J. Hughes, V. Kosmidou, A. Menzies, C. Mould, A. Parker, C. Stevens, S. Watt, S. Hooper, R. Wilson, H. Jayatilake, B.A. Gusterson, C. Cooper, J. Shipley, D. Hargrave, K. Pritchard-Jones, N. Maitland, G. Chenevix-Trench, G.J. Riggins, D.D. Bigner, G. Palmieri, A. Cossu, A. Flanagan, A. Nicholson, J.W. Ho, S.Y. Leung, S.T. Yuen, B.L. Weber, H.F. Seigler, T.L. Darrow, H. Paterson, R. Marais, C.J. Marshall, R. Wooster, M.R. Stratton, and P.A. Futreal Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
11. K.T. Flaherty, I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, J.A. Sosman, P.J. O'Dwyer, R.J. Lee, J.F. Grippo, K. Nolop, and P.B. Chapman Inhibition of mutated, activated BRAF in metastatic melanoma N. Engl. J. Med. 363 2010 809 819
12. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, J. Larkin, R. Dummer, C. Garbe, A. Testori, M. Maio, D. Hogg, P. Lorigan, C. Lebbe, T. Jouary, D. Schadendorf, A. Ribas, S.J. O'Day, J.A. Sosman, J.M. Kirkwood, A.M. Eggermont, B. Dreno, K. Nolop, J. Li, B. Nelson, J. Hou, R.J. Lee, K.T. Flaherty, and G.A. McArthur Improved survival with vemurafenib in melanoma with BRAF V600E mutation N. Engl. J. Med. 364 2011 2507 2516
13. R. Nazarian, H. Shi, Q. Wang, X. Kong, R.C. Koya, H. Lee, Z. Chen, M.K. Lee, N. Attar, H. Sazegar, T. Chodon, S.F. Nelson, G. McArthur, J.A. Sosman, A. Ribas, and R.S. Lo Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature 468 2010 973 977
14. A.J. Miller, and M.C. Mihm Jr. Melanoma N. Engl. J. Med. 355 2006 51 65
15. F.S. Hodi Well-defined melanoma antigens as progression markers for melanoma: insights into differential expression and host response based on stage Clin. Cancer Res. 12 2006 673 678
16. K.W. Kinzler, and B. Vogelstein Cancer-susceptibility genes. Gatekeepers and caretakers Nature 386 1997 761 763
17. W.C. Hahn, C.M. Counter, A.S. Lundberg, R.L. Beijersbergen, M.W. Brooks, and R.A. Weinberg Creation of human tumour cells with defined genetic elements Nature 400 1999 464 468
18. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
19. S.B. Baylin, and J.E. Ohm Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer 6 2006 107 116
20. B. Zhang, X. Pan, G.P. Cobb, and T.A. Anderson MicroRNAs as oncogenes and tumor suppressors Dev. Biol. 302 2007 1 12
21. A.M. Elliott, and M.A. Al-Hajj ABCB8 mediates doxorubicin resistance in melanoma cells by protecting the mitochondrial genome Mol. Cancer Res. 7 2009 79 87
22. C.C. Liang, A.Y. Park, and J.L. Guan In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro Nat. Protoc. 2 2007 329 333
23. J. Vandesompele, K. De Preter, F. Pattyn, B. Poppe, N. Van Roy, A. De Paepe, and F. Speleman Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes Genome Biol 3 2002 (RESEARCH0034)
24. G. Szakacs, J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, and M.M. Gottesman Targeting multidrug resistance in cancer Nat. Rev. Drug Discov. 5 2006 219 234
25. V.C. Janbandhu, A.K. Singh, A. Mukherji, and V. Kumar p65 Negatively regulates transcription of the cyclin E gene J. Biol. Chem. 285 2010 17453 17464
26. Y.X. Chen, J.Y. Fang, H.Y. Zhu, R. Lu, Z.H. Cheng, and D.K. Qiu Histone acetylation regulates p21WAF1 expression in human colon cancer cell lines World J. Gastroenterol. 10 2004 2643 2646
27. B. Stone, M. Schummer, P.J. Paley, L. Thompson, J. Stewart, M. Ford, M. Crawford, N. Urban, K. O'Briant, and B.H. Nelson Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q Int. J. Cancer 104 2003 73 84
28. H. Savli, S. Sirma, B. Nagy, M. Aktan, G. Dincol, and U. Ozbek Real-time PCR analysis of the apoptosis related genes in ATRA treated APL t(15;17) patients Exp. Mol. Med. 35 2003 454 459
29. S. Rozen, and H. Skaletsky Primer3 on the WWW for general users and for biologist programmers Methods Mol. Biol. 132 2000 365 386
30. I. Sachrajda, and M. Ratajewski Mithramycin A suppresses expression of the human melanoma-associated gene ABCB8 Mol. Genet. Genomics 285 2011 57 65
31. K.G. Chen, J.C. Valencia, J.P. Gillet, V.J. Hearing, and M.M. Gottesman Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma Pigment Cell Melanoma Res. 22 2009 740 749
32. F. Piu, N.K. Gauthier, R. Olsson, E.A. Currier, B.W. Lund, G.E. Croston, U. Hacksell, and M.R. Brann Identification of novel subtype selective RAR agonists Biochem. Pharmacol. 71 2005 156 162
33. Y. Zhang, Q. Au, M. Zhang, J.R. Barber, S.C. Ng, and B. Zhang Identification of a small molecule SIRT2 inhibitor with selective tumor cytotoxicity Biochem. Biophys. Res. Commun. 386 2009 729 733
34. L. Dan, O. Klimenkova, M. Klimiankou, J.H. Klusman, M.M. van den Heuvel-Eibrink, D. Reinhardt, K. Welte, and J. Skokowa The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells Haematologica 97 2012 551 559
35. A. Honda, Y. Valogne, M. Bou Nader, C. Brechot, and J. Faivre An intron-retaining splice variant of human cyclin A2, expressed in adult differentiated tissues, induces a G1/S cell cycle arrest in vitro PLoS One 7 2012 e39249
36. L. Wang, D.G. Hurley, W. Watkins, H. Araki, Y. Tamada, A. Muthukaruppan, L. Ranjard, E. Derkac, S. Imoto, S. Miyano, E.J. Crampin, and C.G. Print Cell cycle gene networks are associated with melanoma prognosis PLoS One 7 2012 e34247
37. W.K. Kaufmann, K.R. Nevis, P. Qu, J.G. Ibrahim, T. Zhou, Y. Zhou, D.A. Simpson, J. Helms-Deaton, M. Cordeiro-Stone, D.T. Moore, N.E. Thomas, H. Hao, Z. Liu, J.M. Shields, G.A. Scott, and N.E. Sharpless Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression J. Invest. Dermatol. 128 2008 175 187
38. G. Kiszner, B. Wichmann, I.B. Nemeth, E. Varga, N. Meggyeshazi, I. Teleki, P. Balla, M.E. Maros, K. Penksza, and T. Krenacs Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas Virchows Arch. 464 2014 603 612
39. V.G. Gorgoulis, L.V. Vassiliou, P. Karakaidos, P. Zacharatos, A. Kotsinas, T. Liloglou, M. Venere, R.A. Ditullio Jr., N.G. Kastrinakis, B. Levy, D. Kletsas, A. Yoneta, M. Herlyn, C. Kittas, and T.D. Halazonetis Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions Nature 434 2005 907 913
40. G.G. McGill, M. Horstmann, H.R. Widlund, J. Du, G. Motyckova, E.K. Nishimura, Y.L. Lin, S. Ramaswamy, W. Avery, H.F. Ding, S.A. Jordan, I.J. Jackson, S.J. Korsmeyer, T.R. Golub, and D.E. Fisher Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability Cell 109 2002 707 718
41. A.P. Albino, D.M. Nanus, I.R. Mentle, C. Cordon-Cardo, N.S. McNutt, J. Bressler, and M. Andreeff Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype Oncogene 4 1989 1363 1374
42. K. Omholt, A. Platz, L. Kanter, U. Ringborg, and J. Hansson NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression Clin. Cancer Res. 9 2003 6483 6488
43. K. Satyamoorthy, G. Li, M.R. Gerrero, M.S. Brose, P. Volpe, B.L. Weber, P. Van Belle, D.E. Elder, and M. Herlyn Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation Cancer Res. 63 2003 756 759
44. J.M. Shields, N.E. Thomas, M. Cregger, A.J. Berger, M. Leslie, C. Torrice, H. Hao, S. Penland, J. Arbiser, G. Scott, T. Zhou, M. Bar-Eli, J.E. Bear, C.J. Der, W.K. Kaufmann, D.L. Rimm, and N.E. Sharpless Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma Cancer Res. 67 2007 1502 1512
45. D. Grossman, J.M. McNiff, F. Li, and D.C. Altieri Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma J. Invest. Dermatol. 113 1999 1076 1081
46. H. Takeuchi, D.L. Morton, D. Elashoff, and D.S. Hoon Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine Int. J. Cancer 117 2005 1032 1038
47. D. Grossman, P.J. Kim, J.S. Schechner, and D.C. Altieri Inhibition of melanoma tumor growth in vivo by survivin targeting Proc. Natl. Acad. Sci. U.S.A. 98 2001 635 640
48. M. Chawla-Sarkar, S.I. Bae, F.J. Reu, B.S. Jacobs, D.J. Lindner, and E.C. Borden Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis Cell Death Differ. 11 2004 915 923
49. B.O. Engesaeter, M. Sathermugathevan, T. Hellenes, O. Engebraten, R. Holm, V.A. Florenes, and G.M. Maelandsmo Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells Cancer Biol. Ther. 12 2011 47 58
50. B.J. North, and E. Verdin Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis PLoS One 2 2007 e784
51. L.M. McGlynn, S. Zino, A.I. MacDonald, J. Curle, J.E. Reilly, Z.M. Mohammed, D.C. McMillan, E. Mallon, A.P. Payne, J. Edwards, and P.G. Shiels SIRT2: tumour suppressor or tumour promoter in operable breast cancer? Eur. J. Cancer 50 2014 290 301
52. Y. Hida, Y. Kubo, K. Murao, and S. Arase Strong expression of a longevity-related protein, SIRT1, Bowen's disease Arch. Dermatol. Res. 299 2007 103 106
53. C.K. Singh, J. George, M. Nihal, G. Sabat, R. Kumar, and N. Ahmad Novel downstream molecular targets of SIRT1 in melanoma: a quantitative proteomics approach Oncotarget 5 2014 1987 1999
54. M.J. Wilking, C. Singh, M. Nihal, W. Zhong, and N. Ahmad SIRT1 deacetylase is overexpressed in human melanoma and its small molecule inhibition imparts anti-proliferative response via p53 activation Arch. Biochem. Biophys. 563 2014 94 100
55. M. Ohanna, C. Bonet, K. Bille, M. Allegra, I. Davidson, P. Bahadoran, J.P. Lacour, R. Ballotti, and C. Bertolotto SIRT1 promotes proliferation and inhibits the senescence-like phenotype in human melanoma cells Oncotarget 5 2014 2085 2095
56. N.Y. Frank, A. Margaryan, Y. Huang, T. Schatton, A.M. Waaga-Gasser, M. Gasser, M.H. Sayegh, W. Sadee, and M.H. Frank ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma Cancer Res. 65 2005 4320 4333
57. J.T. Sims, S.S. Ganguly, H. Bennett, J.W. Friend, J. Tepe, and R. Plattner Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-kappaB and HSP27/p38/AKT pathways and by inhibiting ABCB1 PLoS One 8 2013 e55509
58. S.C. Dryden, F.A. Nahhas, J.E. Nowak, A.S. Goustin, and M.A. Tainsky Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle Mol. Cell. Biol. 23 2003 3173 3185
59. T. Inoue, M. Hiratsuka, M. Osaki, and M. Oshimura The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation Cell Cycle 6 2007 1011 1018
60. Y. Li, H. Matsumori, Y. Nakayama, M. Osaki, H. Kojima, A. Kurimasa, H. Ito, S. Mori, M. Katoh, M. Oshimura, and T. Inoue SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis Genes Cells 16 2011 34 45
61. Q. Zuo, W. Wu, X. Li, L. Zhao, and W. Chen HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin Oncol. Rep. 27 2012 819 824
62. W. Jiang, S. Wang, M. Xiao, Y. Lin, L. Zhou, Q. Lei, Y. Xiong, K.L. Guan, and S. Zhao Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase Mol. Cell 43 2011 33 44
63. D.A. Scott, A.D. Richardson, F.V. Filipp, C.A. Knutzen, G.G. Chiang, Z.A. Ronai, A.L. Osterman, and J.W. Smith Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect J. Biol. Chem. 286 2011 42626 42634
64. V. Lennerz, M. Fatho, C. Gentilini, R.A. Frye, A. Lifke, D. Ferel, C. Wolfel, C. Huber, and T. Wolfel The response of autologous T cells to a human melanoma is dominated by mutated neoantigens Proc. Natl. Acad. Sci. U.S.A. 102 2005 16013 16018